

Human genetic evidence supports MAP3K15 inhibition as a therapeutic strategy for diabetes

Abhishek Nag^{1*}, Ryan S. Dhindsa^{2*}, Andrew R. Harper¹, Dimitrios Vitsios¹, Andrea Ahnmark³, Bilada Bilican⁴, Katja Madeyski-Bengtson⁴, Bader Zarrouki³, Quanli Wang², Katherine Smith¹, Dave Smith⁵, Benjamin Challis⁶, Dirk S. Paul¹, Mohammad Bohlooly-Y⁴, Mike Snowden⁷, David Baker⁸, Regina Fritsche-Danielson⁹, Menelas N. Pangalos¹⁰, Slavé Petrovski^{1,11}

¹Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

²Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, USA

³Bioscience Metabolism, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

⁴Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

⁵Emerging Innovations, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁶Translational Science and Experimental Medicine, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁷Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁸Bioscience Metabolism, Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

⁹Early CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

¹⁰BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

¹¹Departments of Medicine and Neurology, University of Melbourne, Royal Melbourne Hospital, Melbourne, Victoria, Australia

*These authors contributed equally

Corresponding author:

Slavé Petrovski

Vice-President, Centre for Genomics Research,

Discovery Sciences, BioPharmaceuticals R&D

AstraZeneca

Cambridge

United Kingdom

Email: slav.petrovski@astrazeneca.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 Diabetes mellitus is a chronic health condition that can result in significant end-organ
3 complications and is estimated to impact at least 8.5% of the global adult population. Here,
4 we performed gene-level collapsing analysis on exome sequences from 454,796 multi-
5 ancestry UK Biobank participants to detect genetic associations with diabetes. Rare non-
6 synonymous variants in *GCK*, *GIGYF1*, *HNF1A*, and *HNF4A* were significantly associated
7 ($P < 1 \times 10^{-8}$) with increased risk of diabetes, whereas rare non-synonymous variants in
8 *MAP3K15* were significantly associated with reduced risk of diabetes. Recessive carriers of
9 rare non-synonymous variants in the X chromosome gene *MAP3K15* had a 30% reduced risk
10 of diabetes (OR=0.70, 95% CI: [0.62,0.79], $P = 5.7 \times 10^{-10}$), along with reduced blood glucose
11 (beta=-0.13, 95% CI: [-0.15,-0.10], $P = 5.5 \times 10^{-18}$) and reduced glycosylated haemoglobin levels
12 (beta=-0.14, 95% CI: [-0.16,-0.11], $P = 1.1 \times 10^{-24}$). Hemizygous males carrying protein-
13 truncating variants (PTVs) in *MAP3K15* demonstrated a 40% reduced risk of diabetes
14 (OR=0.60, 95% CI: [0.45,0.81], $P = 0.0007$). These findings were independently replicated in
15 FinnGen, with a *MAP3K15* PTV associating with decreased risk of both type 1 diabetes
16 (T1DM) and type 2 diabetes (T2DM) ($p < 0.05$). The effect of *MAP3K15* loss on diabetes was
17 independent of body mass index, suggesting its protective effect is unlikely to be mediated via
18 the insulin resistance pathway. Tissue expression profile of *MAP3K15* indicates a possible
19 involvement of pancreatic islet cell or stress response pathways. No safety concerns were
20 identified among heterozygous or recessive *MAP3K15* PTV carriers across over 15,719
21 studied endpoints in the UK Biobank. Human population genetic evidence supports *MAP3K15*
22 inhibition as a novel therapeutic target for diabetes.

23 **Introduction**

24 Diabetes mellitus is a worldwide health concern projected to affect 700 million people by
25 2045¹. It is currently the leading cause of micro- and macrovascular disease, including kidney
26 failure, blindness, heart disease, and lower limb amputations². Characterized by elevated
27 levels of blood glucose, diabetes mellitus is generally categorised into type 1 diabetes mellitus
28 (T1DM), type 2 diabetes mellitus (T2DM), and other rarer forms. T1DM is caused by
29 autoimmune destruction of insulin-producing pancreatic β -cells, while T2DM is primarily
30 caused by peripheral insulin resistance. Both types of diabetes eventually lead to progressive
31 loss of pancreatic β -cells and deficient insulin secretion.

32 Genome wide association studies (GWAS) have implicated over 60 loci in T1DM³ and
33 many hundreds of loci in T2DM^{4,5}. Except for a few loci that map to protein-coding regions
34 (e.g., *PAM*)⁴, the majority reside in non-coding regions of the genome, making it challenging
35 to map the candidate gene and characterise the underlying causal biology. The growing
36 availability of whole-exome sequences in large population-scale biobanks offers
37 unprecedented opportunities to identify protein-coding variants that have demonstrably large
38 effects on human traits and thus potentially constitute more clinically efficacious target
39 opportunities⁶. Identifying loss-of-function variants that protect against disease is of particular
40 interest since these discoveries can provide direct human-validated therapeutic targets⁷⁻⁹.

41 Here, we report a multi-ancestry exome-sequencing association study for diabetes in
42 412,394 exomes from the UK Biobank (UKB). Using our previously described gene-level
43 collapsing framework¹⁰, we identified that recessive loss of the X chromosome gene *MAP3K15*
44 was associated with 40% reduced risk of developing diabetes and decreased circulating
45 glucose and haemoglobin A1c levels. The findings were replicated in the FinnGen study, with
46 a PTV in *MAP3K15* associating with decreased risk of both T1DM and T2DM. Furthermore,
47 the loss of *MAP3K15* was not associated with any apparent on-target adverse phenotypes in
48 a phenome-wide assessment of 15,719 clinical endpoints, supporting *MAP3K15* as a
49 potentially safe target for selective therapeutic inhibition.

50 **Results**

51 **Cohort characteristics and study design**

52 We processed exome sequences from 454,796 UKB participants through our previously
53 described cloud-based pipeline¹⁰. Through stringent quality control, we removed samples with
54 low sequencing quality, low depth of coverage, and from closely related individuals (**Methods**).
55 For this study, we focused on 90 binary clinical phenotypes related to T1DM and T2DM
56 available in the UKB (**Supplementary Table 1A**). In total, there were 39,044 cases that
57 mapped to at least one of the diabetes-related clinical phenotypes, including 35,035 of
58 European ancestry, 2,262 of South Asian ancestry, 249 of East Asian ancestry, and 1,498 of
59 African ancestry. Measurements for quantitative traits related to diabetes, including blood
60 glucose, glycosylated haemoglobin (HbA1c), and body mass index (BMI), were also available
61 for participants (**Supplementary Table 1B**).

62 We employed a gene-level collapsing framework to test the aggregate effect of rare
63 non-synonymous variants in each gene (N=18,762) against each of the diabetes-related
64 clinical phenotypes (**Methods**). Each gene-phenotype combination was tested under 10 non-
65 synonymous collapsing models (including one recessive model) to evaluate a range of genetic
66 architectures, as previously described¹⁰ (**Supplementary Table 2**). We performed two
67 versions of the collapsing analysis: one restricted to individuals of European ancestry and the
68 other a pan-ancestry analysis, as previously described¹⁰ (**Methods**). No inflation of test
69 statistics was observed in the gene-level collapsing analysis for the 90 diabetes-related clinical
70 phenotypes that were tested (median genomic inflation lambda across all models = 1.01).

71 **Rare-variant collapsing analysis**

72 We identified four protein-coding genes significantly associated ($P < 1 \times 10^{-8}$) with at least one
73 diabetes-related clinical phenotype in the European-only analysis (**Figure 1A; Table 1;**
74 **Supplementary Table 3**). Rare non-synonymous variants in *GCK*, *GIGYF1*, and *HNF1A* were
75 associated with increased risk of diabetes, whereas rare non-synonymous variants in
76 *MAP3K15* were associated with reduced risk of diabetes. In the pan-ancestry analysis, all four
77 of these genes maintained statistical significance; one additional gene, *HNF4A*, that was
78 associated with increased risk of diabetes, achieved significance in the pan-ancestry analysis
79 (**Supplementary Table 4**).


80 In our phenome-wide association study of 269,171 European UKB participants¹⁰, the
81 recessive collapsing model, which includes homozygous, hemizygous, and putative
82 compound heterozygous carriers of rare non-synonymous variants, identified unequivocal
83 associations ($P < 1 \times 10^{-8}$) between *MAP3K15* and reduced haemoglobin A1C (HbA1c) and
84 glucose levels¹⁰, accompanied by a suggestive association between *MAP3K15* and
85 decreased risk of diabetes. Consistent with this, a more recent study of 454,787 UKB
86

87 participants¹¹ also found suggestive association between *MAP3K15* and T2DM (OR = 0.85, *P*
88 = 2.8×10^{-6}) under an additive genetic model. Among common variant literature, an intronic
89 variant in *MAP3K15* was one of over 300 novel loci reported in a large trans-ethnic GWAS of
90 T2DM⁵ (OR = 1.14, *P* = 1.4×10^{-8}). In this current study, with an increased sample size of
91 394,695 European participants, the association between *MAP3K15* and diabetes reached
92 study-wide significance ($p < 1 \times 10^{-8}$) in the recessive model (OR = 0.70; 95% CI: [0.62,0.79], *P*
93 = 5.0×10^{-9}). Consistent with our prior findings, the *MAP3K15* qualifying variant (QV) carriers
94 had significantly lower HbA1c levels (beta = -0.14, 95% CI: [-0.16,-0.11], *P* = 3.1×10^{-23}) (**Figure**
95 **1B**) and blood glucose levels (beta = -0.13, 95% CI: [-0.16,-0.10], *P* = 2.5×10^{-17}). In our pan-
96 ancestry analysis, the associations became more significant between *MAP3K15* recessive
97 variants and diabetes (OR = 0.70, 95% CI: [0.62,0.79], *P* = 5.7×10^{-10}), HbA1c (beta = -0.14,
98 95% CI: [-0.16,-0.11], *P* = 1.1×10^{-24}), and blood glucose (beta = -0.13, 95% CI: [-0.15,-0.10],
99 *P* = 5.5×10^{-18}). Collectively, our results implicate loss of *MAP3K15* as a protective factor for
100 diabetes.

101 Most of the protective *MAP3K15* signals emerged for T2DM phenotypes
102 (**Supplementary Table 1A**). To determine if *MAP3K15* loss also protects from T1DM, we
103 defined a T1DM-specific phenotype in the UK Biobank (N = 881 cases) using available
104 diagnostic information (**Methods**). The effect of *MAP3K15* recessive variants on T1DM
105 remained in the protective direction, but the association did not achieve study-wide
106 significance at the current T1DM sample size (OR = 0.52, 95% CI: [0.25,1.09], *P* = 0.09).

107 108 **Complete versus partial loss of *MAP3K15***

109 Given that the *MAP3K15* associations emerged strongest among the recessive model, we
110 next tested whether the effect of *MAP3K15* loss on diabetes could be dose dependent. Since
111 *MAP3K15* resides on chromosome X, hemizygous male PTV carriers are expected to have
112 complete loss of the protein, and heterozygous female carriers are expected to have a 50%
113 loss. Consistent with a dose-dependent effect, we found that hemizygous male carriers of
114 European ancestry (N=1,216) demonstrated a 40% decreased risk of developing diabetes
115 compared to male non-carriers (OR = 0.60, 95% CI: [0.45,0.81], *P* = 7.2×10^{-4})
116 (**Supplementary Table 5**). In comparison, heterozygous female carriers (N = 2,604) had a
117 23% reduced risk of diabetes compared to female non-carriers (OR = 0.77; 95% CI: [0.61,
118 0.99], *P* = 0.04) (**Figure 1C**). Decrease in HbA1c levels were also three times greater in
119 hemizygous male carriers (beta = -0.21, 95% CI: [-0.26,-0.15], *P* = 1.2×10^{-11}) (**Supplementary**
120 **Table 5**) than in heterozygous female carriers (beta = -0.07, 95% CI: [-0.11,-0.04], *P* = 5.3×10^{-5})
121 (**Figure 1D**). The significantly stronger effects observed with complete loss of *MAP3K15* as
122 compared to partial (50%) loss (**Figures 1C and 1D**) suggests an additive protective effect of
123 *MAP3K15* loss on diabetes-related traits.



124
 125
 126 **Figure 1. Genetic associations with diabetes and related traits among the**
 127 **European ancestry participants in the UK Biobank. (A)** Odds ratios and allele
 128 frequencies of gene-level (collapsing) and variant-level (ExWAS) associations
 129 ($p < 1 \times 10^{-8}$) with diabetes diagnoses. **(B)** Effect sizes and allele frequencies of
 130 gene-level (collapsing) and variant-level (ExWAS) associations ($p < 1 \times 10^{-8}$) with
 131 haemoglobin A1c (HbA1c). Allele frequencies on the x-axis are plotted on a log₁₀
 132 scale in both (A) and (B). **(C)** Odds ratios of partial loss (i.e., heterozygous female
 133 PTV carriers) and complete loss (i.e., hemizygous male PTV carriers) of *MAP3K15*
 134 for diabetes and hypertension diagnoses. **(D)** Effect sizes of partial loss (i.e.,
 135 heterozygous female PTV carriers) and complete loss (i.e., hemizygous male PTV
 136 carriers) of *MAP3K15* for various cardiovascular and metabolic traits related to
 137 diabetes. (DBP = Diastolic Blood Pressure, SBP = Systolic Blood Pressure, BMI =
 138 Body Mass Index) **(E)** Lollipop plot depicting *MAP3K15* PTVs (stop gain and
 139 frameshift variants) observed among hemizygous males of European ancestry.
 140 Essential splice variants were not included. The two most frequent PTVs have
 141 been annotated with allele frequencies from participants of European ancestry.
 142 There were no carriers in common to the two PTVs among the European ancestry
 143 males. The y-axis is capped at 40.

144 We also found that the contributing PTVs occurred throughout the *MAP3K15* gene
 145 sequence (**Figure 1E; Supplementary Figure 1**). Two *MAP3K15* PTVs were relatively more

146 frequent and accounted for 74% of the European-ancestry hemizygous male carriers:
147 Arg1122* (MAF = 0.11%) and Arg1136* (MAF = 0.35%) (**Figure 1E; Supplementary Table**
148 **6**). Although proximally close, none of the European-ancestry males carried both PTVs.
149 Consistent with this, the two PTVs were found to be independently associated with reduced
150 risk of diabetes (Arg1122*: OR = 0.33, 95% CI: [0.13,0.80], $P = 0.02$; Arg1136*: OR = 0.60,
151 95% CI: [0.41,0.88], $P = 0.01$) and lower HbA1c levels (Arg1122*: beta = -0.30, 95% CI: [-
152 0.44,-0.15], $P = 4.3 \times 10^{-5}$; Arg1136*: beta = -0.20, 95% CI: [-0.27,-0.12], $P = 1.3 \times 10^{-6}$)
153 (**Supplementary Table 7**). When excluding these two PTVs from the collapsing test, carriers
154 of the remaining 38 ultra-rare *MAP3K15* PTVs observed among the European-ancestry males
155 also had significantly reduced HbA1c levels (beta = -0.16, 95% CI: [-0.28,-0.05], $P = 5.2 \times 10^{-3}$).
156 Due to reduced sample and, thus, statistical power, the association with reduced diabetes
157 risk (OR = 0.84, 95% CI: [0.50,1.39], $P = 0.49$) did not achieve significance among the
158 remaining ultra-rare PTV carriers (**Supplementary Table 7**).

159 160 **Replication analysis**

161 Using summary statistics from the FinnGen study release 5 [N=218,792], we next aimed to
162 replicate the *MAP3K15* findings. The two more frequent *MAP3K15* PTVs (Arg1122* and
163 Arg1136*) were both well-imputed (INFO scores: 0.98 and 0.84, respectively) in the FinnGen
164 dataset. The Arg1122* PTV (rs140104197), which is three times more common in individuals
165 of Finnish descent (MAF = 0.33%) than in UKB Europeans (MAF = 0.11%), was significantly
166 associated with protection from both T1DM (OR = 0.58, $P = 4.9 \times 10^{-4}$) and T2DM (OR = 0.82,
167 $P = 0.04$) (**Supplementary Table 8**). Arg1136* (rs148312150) was less frequent in individuals
168 of Finnish descent compared to Europeans in UKB (MAF: 0.16% versus 0.35%), and it
169 individually did not reach statistical significance with any diabetes-related phenotype in
170 FinnGen. There were no other *MAP3K15* PTVs detected in FinnGen.

171 172 ***MAP3K15* protective PTV signal is not associated with changes in body mass index or** 173 **metabolic derangements**

174 Obesity, which can lead to increased insulin resistance, is a strong risk factor for T2DM. To
175 investigate whether the effect of *MAP3K15* on diabetes is mediated via adiposity, we further
176 tested the effect of complete loss of *MAP3K15* adjusting for BMI. The associations between
177 hemizygous *MAP3K15* PTV carrier status and both HbA1c (BMI-unadjusted: beta = -0.21,
178 95% CI: [-0.15,-0.26], $P = 1.2 \times 10^{-11}$; BMI-adjusted: beta = -0.20, 95% CI: [-0.14,-0.26], $P =$
179 1.1×10^{-11}) and diabetes (BMI-unadjusted: OR = 0.60, 95% CI: [0.45,0.81], $P = 7.2 \times 10^{-4}$; BMI-
180 adjusted: OR = 0.59, 95% CI: [0.43,0.79], $P = 5.3 \times 10^{-4}$) remained consistent after adjusting
181 for BMI, suggesting the protective effect of *MAP3K15* loss on diabetes is unlikely to be
182 mediated via insulin resistance and is likely to benefit individuals irrespective of BMI.

183 Certain genes that influence diabetes risk can also impact other clinically relevant
184 biomarkers. For example, although PTVs in *GIGYF1* are associated with increased risk of
185 diabetes, they are also associated with reduced low-density lipoprotein cholesterol¹². We thus
186 tested whether collapsing analyses of *MAP3K15* rare non-synonymous variants associated
187 with any of 168 NMR-based blood metabolite measurements available for approximately
188 120,000 of the UKB participants. Among the studied metabolites, *MAP3K15* was only
189 associated with reduced glucose (“ptv5pcnt” model, beta = -0.16, 95% CI: [-0.23,-0.10], $P =$
190 4.4×10^{-7}).

191 **Potential *MAP3K15* inhibition safety liabilities**

192 We observed that approximately 1 in every 150 (0.6%) European-ancestry male participants
193 in the UKB has a lifetime systemic absence of functional *MAP3K15*. Given these individuals
194 are participants in a generally healthy cohort such as the UKB provides considerable support
195 to the tolerability of *MAP3K15* inhibition in humans. This is further supported by this gene’s
196 pLI score of 0.0, which is a measure of the tolerance of a given gene to protein-truncating
197 variants¹³.

198 However, we sought to systematically evaluate whether therapeutically inhibiting
199 *MAP3K15* could associate with on-target adverse phenotypes. To achieve this, we surveyed
200 associations between non-synonymous variants in *MAP3K15* and 15,719 clinical phenotypes
201 in the UKB, as described previously¹⁰. We did not observe any significant adverse phenotypic
202 associations ($P < 1 \times 10^{-8}$) in individuals with *MAP3K15* loss (“ptv”, “ptv5pcnt”, and “rec”
203 collapsing models) in either the individual ancestry or the pan-ancestry analysis. We next
204 tested whether there were any other non-diabetes *MAP3K15* associations at a less
205 conservative p-value threshold ($P < 1 \times 10^{-4}$). In the European ancestry participants, there were
206 no associations in the “ptv” or “ptv5pcnt” model even at this more liberal p-value cut-off. There
207 were two associations observed in models that included missense variants: hepatomegaly
208 with splenomegaly and diseases of the tongue (**Supplementary Table 9A**).

209 Finally, as previous animal model studies have highlighted that knockout of *Map3k15*
210 in mice models introduces a hypertensive phenotype¹⁴, we sought to look at this specific
211 phenotype in greater detail. Among the large European sample, there was no evidence of
212 increased risk to hypertension. Instead, the effect of *MAP3K15* PTVs on human blood
213 pressure-related traits seems to be in the protective direction. The hemizygous *MAP3K15* PTV
214 carriers (i.e., complete loss of *MAP3K15*) showed a modest effect in the protective direction
215 for both hypertension (‘*Union#110#110 Essential (primary) hypertension*’: OR = 0.90, 95% CI:
216 [0.80,1.02], $P = 0.10$) and systolic blood pressure (beta = -0.07, 95% CI: [-0.12,-0.01], $P =$
217 0.01) (**Figures 1C and 1D; Supplementary Table 10**). Similarly, among the independent
218 FinnGen cohort, the Finnish-enriched *MAP3K15* PTV (Arg1122* (rs140104197)) that

219 associated strongly with T1DM and T2DM, replicated a modest protective effect on
220 hypertension (OR = 0.84, $P = 8.5 \times 10^{-3}$). Expanding our assessment to *MAP3K15* missense
221 variants, the strongest signal for hypertension arises among participants of South Asian
222 ancestry (N=8,078), where the recessive collapsing model showed an association between
223 *MAP3K15* and a hypertension phenotype ('41202#BlockI10-I15#I10-I15 Hypertensive
224 diseases': OR = 6.33, 95% CI: [3.02,13.28], $P = 4.8 \times 10^{-5}$) (**Supplementary Table 9A**).
225 Although not study-wide significant ($P < 1 \times 10^{-8}$), more importantly, this signal was driven by
226 *MAP3K15* missense variants, with seven hemizygous missense carriers and one hemizygous
227 PTV carrier among affected males of South Asian descent (**Supplementary Table 9B**). A
228 more detailed screen of *MAP3K15* missense variants identified rs56381411 associating with
229 an increased risk of hypertension in FinnGen (MAF = 1.5%, OR = 1.17, $P = 2.4 \times 10^{-7}$).
230 Evaluation of the effect of *MAP3K15* missense variants in recessive form in European ancestry
231 participants revealed a nominally significant association with a blood pressure phenotype in
232 the UK Biobank too ('Union#R030#R03.0 Elevated blood-pressure reading| without diagnosis
233 of hypertension': OR = 1.44, 95% CI: [1.02,2.03], $P = 0.05$).


234 Whereas certain missense variants in *MAP3K15* may increase the risk of hypertension,
235 there is no evidence for PTVs in this gene conferring risk. Collectively, these findings suggest
236 a potential *MAP3K15* allelic series, whereby putative gain-of-function missense variants in
237 might increase the risk of hypertension while PTV (putative loss-of-function) alleles protect
238 against hypertension. Further functional characterisation of variation in *MAP3K15* is required
239 to better understand their variable effects on blood pressure- and diabetes-related traits.
240 Altogether, the lack of association between PTVs in *MAP3K15* and any adverse phenotypes
241 suggest that there is a low human safety risk for selective therapeutic inhibition of *MAP3K15*.

242

243 **Orthogonal evidence**

244 Because *MAP3K15* appears to be associated with reduced risk of T1DM and T2DM and is not
245 associated with BMI, the data suggests that the protective effect is unlikely to be operating
246 through insulin sensitisation. Physiologically, *MAP3K15* encodes a mitogen-activated protein
247 kinase that is known to play a role in regulating cell stress and apoptotic cell-death¹⁵. To gain
248 more insight into potential protective mechanisms, we examined the tissue expression profiles
249 of *MAP3K15* in GTEx¹⁶. *MAP3K15* is most strongly expressed in the adrenal glands and is
250 also expressed at relatively lower levels in the spleen, kidney, pancreas, and pituitary glands
251 (**Figure 2A**). Single-cell expression data from human pancreatic endocrine cells indicate that
252 *MAP3K15* is most strongly expressed in islet cell subpopulations, including α -, β - and δ -
253 cells¹⁷⁻²¹ (**Figure 2B**). Its ubiquitous expression profile in the adrenals could suggest a role in
254 mediating catecholamine biosynthesis or glucocorticoid response²². Alternatively, its effect
255 could be mediated through maintenance of endogenous pancreatic islet cells.


256 To further explore whether *MAP3K15* contributes to the pathophysiology of diabetes
257 in pancreatic cells, we assessed differential gene expression data from a prior study focused
258 on Maturity Onset Diabetes of the Young (MODY)²³, an early-onset, autosomal dominant form
259 of noninsulin-dependent diabetes. In this study, expression profiling was performed on a
260 mouse insulinoma cell line carrying mutations in the MODY-associated gene *Nkx6-1*. In all
261 three mutations tested, including a positive control mutant known to impair *Nkx6-1* as well as
262 two MODY-associated genetic variants, *MAP3K15* was found to be the most significantly
263 upregulated gene (**Figure 2C**). This finding suggests that increased *MAP3K15* activity may
264 mediate the pathophysiology of diabetes, potentially through an increased rate of beta cell
265 loss.



266
267 **Figure 2. Tissue expression profile of *MAP3K15*.** (A) Expression of *MAP3K15* in human
268 tissues contained in the GTEx database. TPM = transcripts per million. We only included
269 tissues with a median TPM > 0.1. (B) *MAP3K15* expression in major subpopulations of
270 human pancreatic cells derived from a previously published single-cell RNA-sequencing
271 dataset^{17–21}. (C) Volcano plot depicting differential gene expression in mouse insulinoma
272 cell lines stably expressing three variants in *Nkx6-1*: two MODY-associated variants
273 (P329L and S317L) and a control mutation known to functionally impair *Nkx6-1*
274 (EEDD321RPPR)²³.

275
276 Orthogonal evidence derived from two *in silico* tools, Gene-SCOUT²⁴ and phenome-wide
277 Mantis-ML²⁵ provide further support for a role of *MAP3K15* in diabetes. Gene-SCOUT provides
278 biomarker fingerprint similarity between any pair of human genes based on UKB exome

279 sequencing cohort statistics using 1,419 quantitative traits²⁴. Entering *MAP3K15* as the seed
 280 gene in this tool highlights *SLC30A8* as having the most similar human biomarker profile to
 281 what is observed for *MAP3K15* (**Figures 3A and 3B; Supplementary Figure 2**). *SLC30A8*,
 282 a zinc transporter gene (ZnT8) expressed in pancreatic islet α - and β -cells, is reported to
 283 have a protective effect against T2DM potentially via increased glucose responsiveness^{26,27}.
 284 Mantis-ML, an automated machine-learning framework designed to identify gene-phenotype
 285 relationships based on compendium of publicly available disease-specific features (such as
 286 tissue expression, preclinical models, genic intolerance, among others), suggests disorders
 287 related to impaired glucose homeostasis, including “diazoxide-resistant diffuse
 288 hyperinsulinism” and “hyperinsulinemic hypoglycaemia” (**Figure 3C**), among the top 1% of
 289 human phenotypes that *MAP3K15* may have a role in (**Supplementary Table 11**). While
 290 mantis-ml does not indicate whether a gene may have a causal versus protective role for a
 291 given phenotype, these results converge on *MAP3K15*'s involvement in diabetes-related
 292 biology. Both these tools provide diverse and independent support of a biological role for
 293 *MAP3K15* in human diabetes.



294
 295 **Figure 3. *MAP3K15* quantitative trait and disease signatures.** (A) Genes with
 296 most similar quantitative trait profiles as *MAP3K15* in the UK Biobank, derived from
 297 Gene-SCOUT²⁴. (B) Linear regression coefficients for HbA1c and glucose from
 298 collapsing analysis models for genes in panel A (genes are sorted from top to bottom
 299 in decreasing order of similarity to *MAP3K15*). QVs = qualifying variants. (C) Mantis
 300 ML²⁵ predictions of *MAP3K15* disease associations.
 301

302 Discussion

303 This exome-sequencing study of 456,796 UKB participants increases our understanding of
304 high-effect size genetic factors involved in both propensity for and protection from diabetes in
305 humans. We found that recessive loss of *MAP3K15* reduces the risk of developing diabetes
306 by approximately 40%. This was supported by the association between recessive loss of
307 *MAP3K15* and decreased HbA1c and blood glucose. Although the protective signal was
308 strongest for T2DM, the effect of *MAP3K15* PTVs was also in the protective direction for T1DM
309 risk in both the UKB and FinnGen. This supports the notion that despite being defined as
310 distinct clinical entities, T1DM and T2DM share some common pathophysiological pathways
311 such as β -cell dysfunction^{28,29}.

312 Crucially, loss-of-function mutations that protect against human disease can act as
313 direct *in vivo* validation of therapeutic targets; thus, *MAP3K15* inhibition could have therapeutic
314 value in both T1DM and T2DM. Given the relatively modest decrease in glucose (0.25 mmol/L)
315 and HbA1c levels (1.36 mmol/mol) that associate with *MAP3K15* loss, one possibility is that
316 the observed protective effect on clinical diabetes is not primarily mediated through glucose /
317 HbA1c reduction. We also found that the protective effect of *MAP3K15* loss is independent of
318 BMI, which might suggest that its effect on diabetes is unrelated to insulin sensitivity, though
319 we note that the relationship between BMI and insulin resistance is correlational. While not
320 currently available for UK Biobank participants, quantitative measures of insulin resistance in
321 *MAP3K15* PTV carriers in future studies could illuminate whether the protective mechanism is
322 indeed unrelated to the insulin resistance pathway. Nonetheless, our results suggest that
323 therapeutic selective inhibition of *MAP3K15* could also benefit patients living with diabetes
324 who are in the low-to-normal BMI range.

325 Through a phenome-wide association study in the 454,796 human participants, we
326 showed that *MAP3K15* loss is not significantly associated with any phenotypes that would
327 suggest safety concerns due to therapeutic inhibition of this target. Prior work observed that
328 knocking out *Map3k15* in mice led to hypertension¹⁴. Interestingly, we found that in humans,
329 PTVs appeared to provide a protective effect on hypertension, whereas certain missense
330 variants in *MAP3K15* appeared to increase the risk of hypertension. Collectively, these results
331 not only highlight possible species-specific differences upon loss of *MAP3K15*, but also
332 suggest an allelic series in humans, in which missense variants exert a spectrum of loss- to
333 gain-of-function effects. Future functional characterisation of clinically associated missense
334 variants and PTVs could provide further insights into this potential allelic series.

335 In our previously published work, *MAP3K15* was one of 15 genes that had unequivocal
336 associations with glucose and/or HbA1c¹⁰. What sets *MAP3K15* apart from these other genes

337 is that, with the addition of 150,000 more exomes, we also observe a statistically significant
338 reduced risk for diabetes diagnosis, in addition to the biomarker associations. This finding has
339 important implications for the interpretation of genetic biomarker associations. Crucially, not
340 all genetic associations with clinically relevant biomarkers will be related to the
341 pathophysiology of the underlying disease. Here, anchoring biomarker genetic signals with
342 relevant clinical endpoints can help identify those that are more likely to modify the underlying
343 disease. Therapeutically, this suggests that inhibiting *MAP3K15* may target the core
344 pathophysiology of the disease process rather than targeting reduced blood glucose.

345 The tissue expression profile of *MAP3K15* demonstrates predominant expression in
346 adrenal glands and several islet cell subpopulations, suggesting that *MAP3K15* might be
347 involved in pancreatic islet cell functional maintenance and / or stress response pathways.
348 Dysregulation of stress response in diabetes^{30,31} and the role of *ASK* (*MAP* kinase) family of
349 genes in regulating stress response (e.g., apoptosis, inflammation) to external stimuli^{14,15} offer
350 further support to these mechanisms. These provide important clues regarding the otherwise
351 unknown pathways that mediate the protective effect of *MAP3K15* natural inhibition on
352 diabetes.

353
354

355

356

357 **Methods**

358 **Cohorts**

359 Discovery genetic association studies were performed using the 454,796 exomes available in
360 the UK Biobank (UKB) cohort³². The UKB is a prospective study of approximately 500,000
361 participants aged 40–69 years at time of recruitment. Participants were recruited in the UK
362 between 2006 and 2010 and are continuously followed. The average age at recruitment for
363 sequenced individuals was 56.5 years and 54% of the sequenced cohort is of female genetic
364 sex. Participant data include health records that are periodically updated by the UKB, self-
365 reported survey information, linkage to death and cancer registries, collection of urine and
366 blood biomarkers, imaging data, accelerometer data and various other phenotypic end points.
367 All study participants provided informed consent and the UK Biobank has approval from the
368 North-West Multi-centre Research Ethics Committee (MREC; 11/NW/0382).

369 Replication of the findings in the UKB was performed using the summary statistics from
370 the FinnGen study. The FinnGen cohort (release 5) includes 218,792 individuals from Finland
371 with genotype and health registry data. Phenotypes have been derived from nationwide health
372 registries. Patients and control subjects in FinnGen provided informed consent for biobank
373 research, based on the Finnish Biobank Act. Alternatively, older research cohorts, collected
374 prior the start of FinnGen (in August 2017), were collected based on study-specific consents
375 and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory
376 Authority for Welfare and Health. Recruitment protocols followed the biobank protocols
377 approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki
378 and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen
379 study is approved by Finnish Institute for Health and Welfare.

380 381 **Phenotypes**

382 We harmonized the UKB phenotype data as previously described¹⁰. Briefly, we used PEACOK
383 and union mapping to parse binary and quantitative traits included in the February 2020 UKB
384 release (accessed March 27, 2020; UKB application 26041). Here, we considered 90 binary
385 (clinical) phenotypes related to diabetes available in the UKB (**Supplementary Tables 1A**),
386 three quantitative traits related to diabetes (blood glucose, glycosylated haemoglobin and
387 body mass index), and two quantitative traits related to hypertension (systolic blood pressure
388 (SBP) and diastolic blood pressure (DBP)) (**Supplementary Tables 1B**).

389 Additionally, for a type 1 diabetes (T1DM)-specific analysis, we defined the case population
390 using ICD-9 and ICD-10 codes that captured T1DM diagnoses and the control population by
391 excluding participants with any diabetes diagnoses.

392 For analyses involving SBP and DBP, we adjusted for commonly prescribed blood pressure
393 medications (**Supplementary Table 12**).

394 395 **Genetic data**

396 Exome sequencing data for 454,988 UKB participants were generated at the Regeneron
397 Genetics Center (RGC) as part of a pre-competitive data generation collaboration between
398 AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, Pfizer,
399 Regeneron and Takeda with the UKB. Genomic DNA underwent paired-end 75-bp whole-
400 exome sequencing at Regeneron Pharmaceuticals using the IDT xGen v1 capture kit on the
401 NovaSeq6000 platform. Conversion of sequencing data in BCL format to FASTQ format and
402 the assignments of paired-end sequence reads to samples were based on 10-base barcodes,
403 using bcl2fastq v2.19.0. Initial quality control was performed by Regeneron and included sex
404 discordance, contamination, unresolved duplicate sequences and discordance with
405 microarray genotyping data checks.

406 In FinnGen, genotyping of the samples was done using a ThermoFisher Axiom custom array.
407 In addition to the core GWAS markers (about 500,000), it contains 116,402 coding variants
408 enriched in Finland, 10,800 specific markers for the HLA/KIR region, 14,900 ClinVar variants,
409 4,600 pharmacogenomic variants and 57,000 selected markers.

410 411 **AstraZeneca Centre for Genomics Research (CGR) bioinformatics pipeline**

412 The 454,796 UKB exome sequences were re-processed at AstraZeneca from their unaligned
413 FASTQ state. A custom-built Amazon Web Services (AWS) cloud compute platform running
414 Illumina DRAGEN Bio-IT Platform Germline Pipeline v3.0.7 was used to align the reads to the
415 GRCh38 genome reference and perform single-nucleotide variant (SNV) and insertion and
416 deletion (indel) calling. SNVs and indels were annotated using SnpEFF v4.3³³ against
417 Ensembl Build 38.92. We further annotated all variants with their genome Aggregation
418 Database (gnomAD) MAFs (gnomAD v2.1.1 mapped to GRCh38)¹³. We also annotated
419 variants using MTR score³⁴ to identify if they mapped to genic regions under constraint for
420 missense variants and REVEL scores³⁵ for their predicted deleteriousness.

421 422 **Additional quality control**

423 To complement the quality control performed by Regeneron Genomics Centre, we passed the
424 UKB exome sequences through our internal bioinformatics pipeline as previously described¹⁰.
425 Briefly, for UKB, we excluded from our analyses an additional 122 sequences that achieved a
426 VerifyBAMID freemix (measure of DNA contamination) of more than 4%, and an additional 5
427 sequences where less than 94.5% of the consensus coding sequence (CCDS release 22)
428 achieved a minimum of ten-fold read depth. The cohort was also screened to remove
429 participants that were second-degree relatives or closer (equivalent to kinship coefficient >

430 0.0884), as determined using the --kinship function in KING v2.2.3³⁶. After the above quality
431 control steps, there remained 412,394 unrelated UKB sequences of any genetic ancestry that
432 were available for analyses presented in this study.

433 434 **Genetic ancestry**

435 The primary discovery analysis was performed in UKB participants of European ancestry. We
436 used the available exome sequencing data to perform genetic ancestry prediction in PEDDY
437 v0.4.2. We leveraged sequences from the 1,000 Genomes Project as population references³⁷
438 for ancestry estimation. 394,695 (93%) of the 422,488 unrelated UKB participants – that had
439 European ancestry prediction >0.99 and were within 4 SD of the means for the top four
440 principal components – were selected for the European-ancestry case-control analyses. We
441 also used the PEDDY-derived ancestry predictions to identify non-European ancestry
442 populations that had at least 1,000 individuals with exome sequences to perform pan-ancestry
443 collapsing analyses (see the section ‘Collapsing analyses’). This identified 7,412 African,
444 2,209 East Asian and 8,078 South Asian UKB participants based on predicted ancestry >0.95
445 for the respective ancestries.

446 447 **Discovery analyses**

448 Collapsing analyses

449 We performed our previously described gene-level collapsing analysis framework¹⁰ for 90
450 binary and 5 quantitative traits related to diabetes. We included 10 non-synonymous
451 collapsing models, including 9 dominant and one recessive model, plus an additional
452 synonymous variant model as an empirical negative control (**Supplementary Table 2**). For
453 the dominant collapsing models, the carriers of at least one qualifying variant (QV) in a gene
454 were compared to the non-carriers. In the recessive model, individuals with two copies of QVs
455 either in homozygous or putatively compound heterozygous form were compared to the non-
456 carriers. Hemizygous genotypes for X chromosome genes also qualified for the recessive
457 model.

458 Using SnpEff annotations, we defined synonymous variants as those annotated as
459 ‘synonymous_variant’. We defined PTVs as variants annotated as exon_loss_variant,
460 frameshift_variant, start_lost, stop_gained, stop_lost, splice_acceptor_variant,
461 splice_donor_variant, gene_fusion, bidirectional_gene_fusion, rare_amino_acid_variant, and
462 transcript_ablation. We defined missense as: missense_variant_splice_region_variant, and
463 missense_variant. Nonsynonymous variants included: exon_loss_variant, frameshift_variant,
464 start_lost, stop_gained, stop_lost, splice_acceptor_variant, splice_donor_variant,
465 gene_fusion, bidirectional_gene_fusion, rare_amino_acid_variant, transcript_ablation,
466 conservative_inframe_deletion, conservative_inframe_insertion,

467 disruptive_inframe_insertion, disruptive_inframe_deletion,
468 missense_variant_splice_region_variant, missense_variant, and protein_altering_variant.

469 For binary traits, the difference in the proportion of cases and controls carrying QVs in
470 a gene was tested using a Fisher's exact two-sided test. For quantitative traits, the difference
471 in mean between the carriers and non-carriers of QVs was determined by fitting a linear
472 regression model, correcting for age, sex and medication intake (for SBP and DBP).

473 For all models, we applied the following quality control filters: minimum coverage 10X;
474 annotation in CCDS transcripts (release 22; approximately 34 Mb); at most 80% alternate
475 reads in homozygous genotypes; percent of alternate reads in heterozygous variants ≥ 0.25
476 and ≤ 0.8 ; binomial test of alternate allele proportion departure from 50% in heterozygous
477 state $P > 1 \times 10^{-6}$; GQ ≥ 20 ; FS ≤ 200 (indels) ≤ 60 (SNVs); MQ ≥ 40 ; QUAL ≥ 30 ; read position
478 rank sum score ≥ -2 ; MQRS ≥ -8 ; DRAGEN variant status = PASS; the variant site achieved
479 ten-fold coverage in $\geq 25\%$ of gnomAD exomes, and if the variant was observed in gnomAD
480 exomes, the variant achieved exome z-score ≥ -2.0 and exome MQ ≥ 30 . We excluded 46
481 genes that we previously found associated with batch effects¹⁰.

482

483 Pan-ancestry collapsing analyses

484 We performed additional collapsing analysis in each individual non-European ancestral
485 population as described above. For binary traits, we then performed a pan-ancestry analysis
486 using our previously introduced approach¹⁰ of applying a Cochran-Mantel-Haenszel test to
487 generate combined 2x2xN stratified P-values, with N representing up to all four genetic
488 ancestry groups. For quantitative traits, the pan-ancestry analysis was performed using a
489 linear regression model that included the following covariates: age, sex, categorical ancestry
490 (European, African, East Asian or South Asian), and top five ancestry principal components.

491

492 Variant-level (ExWAS) analyses

493 We performed variant-level association tests in addition to the gene-level collapsing analyses
494 for the 90 binary and 5 quantitative traits related to diabetes. We tested 3.3 million variants
495 identified in at least six individuals from the 394,695 predominantly unrelated European
496 ancestry UKB exomes as previously described¹⁰. In summary, variants were required to pass
497 the following quality control criteria: minimum coverage 10X; percent of alternate reads in
498 heterozygous variants ≥ 0.2 ; binomial test of alternate allele proportion departure from 50% in
499 heterozygous state $P > 1 \times 10^{-6}$; genotype quality score (GQ) ≥ 20 ; Fisher's strand bias score
500 (FS) ≤ 200 (indels) ≤ 60 (SNVs); mapping quality score (MQ) ≥ 40 ; quality score (QUAL) ≥ 30 ;
501 read position rank sum score (RPRS) ≥ -2 ; mapping quality rank sum score (MQRS) ≥ -8 ;
502 DRAGEN variant status = PASS; variant site is not missing (that is, less than 10X coverage)
503 in 10% or more of sequences; the variant did not fail any of the aforementioned quality control

504 in 5% or more of sequences; the variant site achieved tenfold coverage in 30% or more of
505 gnomAD exomes, and if the variant was observed in gnomAD exomes, 50% or more of the
506 time those variant calls passed the gnomAD quality control filters (gnomAD exome
507 AC/AC_raw \geq 50%). P values were generated adopting a Fisher's exact two-sided test. Three
508 distinct genetic models were studied for binary traits: allelic (A versus B allele), dominant (AA
509 + AB versus BB) and recessive (AA versus AB + BB), where A denotes the alternative allele
510 and B denotes the reference allele. For quantitative traits, we adopted a linear regression
511 (correcting for age and sex) and replaced the allelic model with a genotypic (AA versus AB
512 versus BB) test.

513 514 Phenome-wide analysis for *MAP3K15*

515 We performed a phenome-wide collapsing analysis for *MAP3K15* with 15,719 binary
516 phenotypes for each individual ancestry in the UKB. We harmonized and union mapped these
517 phenotype data as previously described¹⁰. We included all 11 collapsing models in the
518 PheWAS, as described above. The methodology used here was identical to our previously
519 published PheWAS on 281,104 UKB participants¹⁰.

520 521 P-value threshold

522 We defined the study-wide significance threshold as $p < 1 \times 10^{-8}$. We have previously shown
523 using an n-of-1 permutation approach and the empirical null synonymous model that this
524 threshold corresponds to a false positive rate of 9 and 2, respectively, out of ~346.5 million
525 tests for binary traits in the setting of collapsing analysis PheWAS¹⁰.

526 527 **Replication analyses**

528 We performed replication analysis of the association between *MAP3K15* and diabetes using
529 the publicly available results from the GWAS in the FinnGen cohort. We accessed the
530 association statistics for the phenome-wide analysis of non-synonymous variants within
531 *MAP3K15* through the FinnGen portal (release 5).

532 533 **Secondary association analyses**

534 A total of 40 unique PTVs in *MAP3K15* were observed among the hemizygous male carriers.
535 Two of these PTVs (Arg1122* and Arg1136*) were relatively more frequent. We excluded
536 carriers of these two alleles and re-performed the collapsing analyses for the remaining
537 *MAP3K15* PTVs: Fisher's exact test for diabetes ('20002#1220#diabetes') and linear
538 regression for HbA1c.

539 To determine whether the effect of complete loss of *MAP3K15* on diabetes is mediated
540 via adiposity or the insulin resistance pathway, we performed additional analyses in which we

541 regressed HbA1c and the diabetes phenotype ('20002#1220#diabetes') on *MAP3K15* PTV
542 carrier status in males, with BMI as the covariate.

543 To investigate the joint effects of complete loss of *MAP3K15* and a nearby significantly
544 associated indel in *PDHA1* (X-19360844-AAC-A), a gene that overlaps the 3'-UTR of
545 *MAP3K15*, we regressed HbA1c and the diabetes phenotype ('20002#1220#diabetes') on the
546 carrier status for the two frequent *MAP3K15* PTVs (Arg1122* and Arg1136*) and the *PDHA1*
547 indel in males.

548 549 **Expression analyses**

550 We studied previously published bulk RNA-sequencing data available from a mouse
551 insulinoma cell line (β -TC-6) transfected with three different clones carrying MODY-associated
552 variants in NKX6-125. We extracted the DESeq2-derived log fold changes, p-values, and FDR
553 values from the supplementary data. We determined tissue expression using the GTEx portal
554 (<http://gtexportal.org/home/>). For single-cell RNA-sequencing analysis, we examined eight
555 previously published datasets using tissue from human pancreatic islets spanning 27 healthy
556 donors, five technologies, and four laboratories¹⁷⁻²¹. Data was integrated using Seurat, as
557 previously described³⁸.

558 559 **Gene-SCOUT**

560 The tool Gene-SCOUT²⁴ estimates similarity between genes by leveraging association
561 statistics from the collapsing analysis across 1,419 quantitative traits available in the UKB. We
562 utilised this tool to identify genes that were most similar to the 'seed gene' *MAP3K15*.

563 564 **Mantis-ML**

565 Mantis-ML²⁵ is a gene prioritisation machine learning framework, integrating a diverse set of
566 annotations, including intolerance to variation, tissue expression and animal models. We used
567 this tool to obtain the top disease predictions for *MAP3K15* across 2,536 diseases parsed from
568 Open Targets.

569 **Tables**

Gene Name	Chr	UKB diabetes-related clinical phenotype	Most significant collapsing model	Frequency of QV carriers		OR [95% CI]	P
				Cases	Controls		
<i>GCK</i>	7	2443#Diabetes diagnosed by doctor	URmtr	0.25%	0.04%	6.75 [4.80,9.50]	3.14x10 ⁻²¹
<i>GIGYF1</i>	7	Union#E11#E11 Non-insulin-dependent diabetes mellitus	ptv	0.13%	0.03%	4.00 [2.74,5.84]	9.98x10 ⁻¹¹
<i>HNF1A</i>	12	Source of report of E14 (unspecified diabetes mellitus)	ptv5pcnt	0.07%	0.00%	39.18 [11.06,138.86]	1.39x10 ⁻¹⁰
<i>MAP3K15</i>	X	Union#E14#E14 Unspecified diabetes mellitus	rec	1.25%	1.77%	0.70 [0.62,0.79]	5.00x10 ⁻⁹

570 **Table 1: Genes significantly associated with at least one diabetes-related clinical**
571 **phenotype in the gene-level collapsing analysis among European ancestry**
572 **participants in the UK Biobank**

573 Genes across the exome were tested under 10 different non-synonymous collapsing models
574 with 90 diabetes-related clinical phenotypes available in the UK Biobank. The most
575 significant diabetes-related clinical phenotype and the corresponding association statistics
576 have been provided for the four genes that were significantly associated ($p < 1 \times 10^{-8}$) with at
577 least one diabetes-related clinical phenotype among European ancestry participants.

578 (Chr=Chromosome; QV=Qualifying Variant; OR=Odds Ratio, CI=Confidence Intervals)

579

580 **Competing Interests**

581 A.N., R.S.D., A.R.H, D.V., A.A., B.B., K.M., B.Z., Q.W., K.S., D.S., B.C., D.S.P., MB., M.S.,
582 D.B., R.F., M.N.P., and S.P are current employees and/or stockholders of AstraZeneca.

583 **References**

584

- 585 1. Saeedi, P. *et al.* Global and regional diabetes prevalence estimates for 2019 and
586 projections for 2030 and 2045: Results from the International Diabetes Federation
587 Diabetes Atlas, 9(th) edition. *Diabetes research and clinical practice* **157**, 107843
588 (2019).
- 589 2. Deshpande, A. D., Harris-Hayes, M. & Schootman, M. Epidemiology of diabetes and
590 diabetes-related complications. *Physical therapy* **88**, 1254–1264 (2008).
- 591 3. Pociot, F. Type 1 diabetes genome-wide association studies: not to be lost in
592 translation. *Clinical & translational immunology* **6**, e162 (2017).
- 593 4. Mahajan, A. *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using
594 high-density imputation and islet-specific epigenome maps. *Nature genetics* **50**, 1505–
595 1513 (2018).
- 596 5. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular
597 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nature*
598 *genetics* **52**, 680–691 (2020).
- 599 6. Walter, K. *et al.* The UK10K project identifies rare variants in health and disease. *Nature*
600 **526**, 82–90 (2015).
- 601 7. Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence variations in
602 PCSK9, low LDL, and protection against coronary heart disease. *The New England*
603 *journal of medicine* **354**, (2006).
- 604 8. Akbari, P. *et al.* Sequencing of 640,000 exomes identifies GPR75 variants associated
605 with protection from obesity. *Science (New York, N.Y.)* **373**, (2021).
- 606 9. Abul-Husn, N. S. *et al.* A Protein-Truncating HSD17B13 Variant and Protection from
607 Chronic Liver Disease. *New England Journal of Medicine* **378**, (2018).
- 608 10. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank
609 exomes. *Nature* (2021) doi:10.1038/s41586-021-03855-y.
- 610 11. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank
611 participants. *Nature* (2021) doi:10.1038/s41586-021-04103-z.
- 612 12. Aimee M. Deaton *et al.* Gene-level analysis of rare variants in 379,066 whole exome
613 sequences identifies an association of GIGYF1 loss of function with type 2 diabetes.
614 *Scientific Reports* **11**, (2021).
- 615 13. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
616 141,456 humans. *Nature* **581**, (2020).
- 617 14. Naguro, I. *et al.* ASK3 responds to osmotic stress and regulates blood pressure by
618 suppressing WNK1-SPAK/OSR1 signaling in the kidney. *Nature communications* **3**,
619 1285 (2012).
- 620 15. Hattori, K., Naguro, I., Runchel, C. & Ichijo, H. The roles of ASK family proteins in stress
621 responses and diseases. *Cell communication and signaling : CCS* **7**, 9 (2009).
- 622 16. Carithers, L. J. & Moore, H. M. The Genotype-Tissue Expression (GTEx) Project.
623 *Biopreservation and biobanking* **13**, (2015).
- 624 17. Lawlor, N. *et al.* Single-cell transcriptomes identify human islet cell signatures and
625 reveal cell-type-specific expression changes in type 2 diabetes. *Genome research* **27**,
626 208–222 (2017).
- 627 18. Grün, D. *et al.* De Novo Prediction of Stem Cell Identity using Single-Cell Transcriptome
628 Data. *Cell stem cell* **19**, 266–277 (2016).
- 629 19. Muraro, M. J. *et al.* A Single-Cell Transcriptome Atlas of the Human Pancreas. *Cell*
630 *systems* **3**, 385-394.e3 (2016).
- 631 20. Baron, M. *et al.* A Single-Cell Transcriptomic Map of the Human and Mouse Pancreas
632 Reveals Inter- and Intra-cell Population Structure. *Cell systems* **3**, 346-360.e4 (2016).
- 633 21. Segerstolpe, Å. *et al.* Single-Cell Transcriptome Profiling of Human Pancreatic Islets in
634 Health and Type 2 Diabetes. *Cell metabolism* **24**, 593–607 (2016).
- 635 22. Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science (New*
636 *York, N.Y.)* **347**, (2015).

- 637 23. Mohan, V. *et al.* Comprehensive genomic analysis identifies pathogenic variants in
638 maturity-onset diabetes of the young (MODY) patients in South India. *BMC medical*
639 *genetics* **19**, 22 (2018).
- 640 24. Lawrence Middleton *et al.* Gene-SCOUT: identifying genes with similar continuous trait
641 fingerprints from phenome-wide association analyses. *Nucleic Acids Res (in*
642 *submission)*.
- 643 25. Vitsios, D. & Petrovski, S. Mantis-ml: Disease-Agnostic Gene Prioritization from High-
644 Throughput Genomic Screens by Stochastic Semi-supervised Learning. *American*
645 *journal of human genetics* **106**, 659–678 (2020).
- 646 26. Dwivedi, O. P. *et al.* Loss of ZnT8 function protects against diabetes by enhanced
647 insulin secretion. *Nature genetics* **51**, 1596–1606 (2019).
- 648 27. Kleiner, S. *et al.* Mice harboring the human SLC30A8 R138X loss-of-function mutation
649 have increased insulin secretory capacity. *Proceedings of the National Academy of*
650 *Sciences of the United States of America* **115**, E7642–E7649 (2018).
- 651 28. Ahlqvist, E. *et al.* Novel subgroups of adult-onset diabetes and their association with
652 outcomes: a data-driven cluster analysis of six variables. *The lancet. Diabetes &*
653 *endocrinology* **6**, 361–369 (2018).
- 654 29. Cnop, M. *et al.* Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes:
655 many differences, few similarities. *Diabetes* **54 Suppl 2**, S97-107 (2005).
- 656 30. Surwit, R. S., Schneider, M. S. & Feinglos, M. N. Stress and diabetes mellitus. *Diabetes*
657 *care* **15**, 1413–1422 (1992).
- 658 31. Chiodini, I. *et al.* Cortisol secretion in patients with type 2 diabetes: relationship with
659 chronic complications. *Diabetes care* **30**, 83–88 (2007).
- 660 32. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
661 *Nature* **562**, 203–209 (2018).
- 662 33. Cingolani, P. *et al.* A program for annotating and predicting the effects of single
663 nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster*
664 strain w1118; iso-2; iso-3. *Fly* **6**, 80–92 (2012).
- 665 34. Traynelis, J. *et al.* Optimizing genomic medicine in epilepsy through a gene-customized
666 approach to missense variant interpretation. *Genome research* **27**, 1715–1729 (2017).
- 667 35. Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of
668 Rare Missense Variants. *American journal of human genetics* **99**, 877–885 (2016).
- 669 36. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
670 *Bioinformatics* **26**, (2010).
- 671 37. Auton, A. *et al.* A global reference for human genetic variation. *Nature* vol. 526 (2015).
- 672 38. Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, (2019).
- 673
- 674
- 675